GlassScriptPhysician profile
Heather Varney
NPI 1164884938
$9,031.31
in general payments reported to CMS, 2019-2025
42 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,381 · 2022: $1,689 · 2023: $1,760 · 2024: $1,630 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,961.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,659.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,013.90 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $917.76 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $709.81 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $567.26 | 2021-2025 | |
| Glaxosmithkline, LLC. | $548.34 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $460.16 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $426.49 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $315.82 | 2021-2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $256.44 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.16 | 2021-2023 | Synjardy |
| Amarin Pharma, INC. | $188.89 | 2021-2022 | |
| Esperion Therapeutics, INC. | $145.19 | 2021 | |
| Merck Sharp & Dohme LLC | $137.54 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $133.71 | 2022-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Varney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.